BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Methods Development

WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates

Under the partnership, AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing, ADC conjugation process developm...

July 08, 2022 | News

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...

July 05, 2022 | News

Biosynth Carbosynth Expands Peptide Offering with Acquisition of Pepscan

Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition o...

July 01, 2022 | News

Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shiga, Japan

The new blister packaging equipment is identical to that available across Catalent's clinical supply services network, offering maximum access and flexibil...

June 30, 2022 | News

WuXi STA Opens A High-Potency API Plant

The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...

June 29, 2022 | News

Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs) Merck now one of industry’s largest manufacturer...

June 24, 2022 | News

WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes

WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-...

June 06, 2022 | News

Biomerics Announces Image Guided Intervention (IGI) Division

The goal of image-guided intervention systems is to increase the clinician's spatial navigation abilities while reducing the mental burden associated with ...

May 03, 2022 | News

Merck Advances BioProcessing Capabilities with Acquisition of MAST® Platform from Lonza

Merck to become first company to offer a fully integrated ecosystem for advanced process technologies Brings biopharmaceutical industry closer to digita...

April 14, 2022 | News

WuXi Biologics Achieved Record Growth and Profitability in 2021

WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group," stock code: 2269.HK), a global Contract Research, Development and Manufacturing Organization...

March 23, 2022 | News

I Peace triples GMP cell manufacturing by expanding CDMO facility

The facility's expansion, designed to conform to GMP standard, is now almost complete and is expected to start manufacturing cGMP grade cells in April this...

March 15, 2022 | News

Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development

CD34+ cell lots in a range of sizes also now available with high-resolution HLA information, eliminating the need for cumbersome and costly HLA screening...

March 08, 2022 | News

HCmed, Formosa Lab, and Formosa Pharma Signed MoU to Form a Global CDMO for Inhalation Treatment Drugs

By integrating HCmed's vibrating mesh nebulizers, Formosa Laboratories' drug development and manufacturing capabilities, and Formosa Pharmaceuticals' APNT ...

March 07, 2022 | News

WuXi STA Passes the First EMA Drug Product Pre-Approval Inspection at its Wuxi City Site

The PAI focused on the drug product manufacturing of an innovative drug for one of WuXi STA’s partners. During a 5-day remote inspection from Novembe...

March 04, 2022 | News

Stay Connected